Table 1 Characteristics of included studies.
Diagnostic criteria | Drug therapy, n (drug dose) | Treatment duration (weeks) | Age range (mean age) | Male/female ratio | Recruitment location | Functioning measures | Number of samples measuring functioning | QOL measures | Number of samples measuring QOL | Funding source | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Almeida-Montes (2005) | DSM-IV-TR | Fluoxetine, 12 (20 mg/d); Pill-PBO, 11 | 6 | 8–14 (11.5) | 1.86 | Mexico | CGAS (clinician rated) | 16 (Fluoxetine, 7; Pill-PBO, 9) | No | No | No |
Emslie (1997) | DSM-III-R | Fluoxetine, 48 (20 mg/d); Pill-PBO,48 | 8 | 7–17 (12.4) | 1.18 | USA | CGAS (clinician-rated) | 96 (Fluoxetine, 48; Pill-PBO,48) | No | No | No |
Emslie (2002a) | DSM-IV | Fluoxetine, 109 (10–20 mg/d); Pill-PBO, 110 | 9 | 8–18 (12.7) | 1.03 | USA | GAF (clinician-rated) | 190 (Fluoxetine, 104; Pill-PBO, 86) | No | No | EliLilly |
Findling (2009) | DSM-IV | Fluoxetine, 18 (10–20 mg/d); Pill-PBO, 16 | 8 | 12–17 (16.5) | 5.80 | USA | CGAS (clinician-rated) | 30 (Fluoxetine, 16; Pill-PBO, 14) | No | No | Eli Lilly |
March (2004) | DSM-IV | Fluoxetine, 109 (10–40 mg/d); Pill-PBO, 112 | 12 | 12–17 (14.6) | 0.84 | USA | CGAS (clinician-rated) | 194 (Fluoxetine, 98; Pill-PBO, 96) | PQ-LES-Q | 190 | No |
Berard (2006) | DSM-IV | Paroxetine, 187 (20–40 mg/d); Pill-PBO, 99 | 12 | 13–18 (15.6) | 0.50 | Belgium, Italy, Spain, United Kingdom, Holland, Canada, South Africa, United Arab Emirates, Argentina and Mexico | CGAS (clinician-rated) | 193 (Paroxetine, 127; Pill-PBO, 66) | EUROQOL | 184 | GlaxoSmithKline |
Emslie (2006) | DSM-IV | Paroxetine, 104 (10–50 mg/d); Pill-PBO, 102 | 8 | 7–17 (12.0) | 1.14 | USA and Canada | GAF (clinician-rated) | 187 (Paroxetine, 92; Pill-PBO, 95) | No | No | GlaxoSmithKline |
Noury (2015) | DSM-III-R | Paroxetine, 93 (20–60 mg/d); Imipramine, 95 (200–300 mg/d); Pill-PBO, 87 | 8 | 12–18 (14.9) | 0.61 | USA and Canada | AFC (self-rated) | 179 (Paroxetine, 60; Imipramine, 57; Pill-PBO, 62) | SIP | 188 | GlaxoSmithKline |
Wagner (2003) | DSM-IV | Sertraline, 189 (50–200 mg/d); Pill-PBO, 187 | 10 | 6–17 (NA) | 0.96 | USA, India, Canada, Costa Rica and Mexico | CGAS* (self-rated) | 364 (Sertralin, 185; Pill-PBO, 179) | PQ-LES-Q | 364 | Pfizer |
Wagner (2004) | DSM-IV | Citalopram, 93 (20–40 mg/d); Pill-PBO, 85 | 8 | 7–17 (12.1) | 0.87 | USA | CGAS (clinician-rated) | 168 (Citalopram,87; Pill-PBO, 81) | No | No | Forest Laboratories |
Emslie (2009) | DSM-IV | Escitalopram,158 (10–20 mg/d); Pill-PBO, 158 | 8 | 12–17 (14.6) | 0.70 | USA | CGAS (clinician-rated) | 311 (Escitalopram, 154; Pill-PBO, 157) | No | No | Forest Laboratories |
Wagner (2006) | DSM-IV | Escitalopram,132 (10–20 mg/d); Pill-PBO, 136 | 8 | 6–17 (12.3) | 0.93 | USA | CGAS (clinician-rated) | 261 (Escitalopram, 129; Pill-PBO, 132) | No | No | Forest Laboratories |
Emslie (2002b) | DSM-IV | Nefazodone, 99 (100–400 mg/d); Pill-PBO, 96 | 8 | 12–17 (NA) | 0.70 | NA | CGAS (clinician-rated) | 195 (Nefazodone,99; Pill-PBO, 96) | No | No | Bristol-Myers Squibb |
Geller (1990) | DSM-III and RDC | Nortriptyline, 12 (10–140 mg/d); Pill-PBO, 19 | 8 | 12–17 (14.3) | 1.21 | USA | CGAS (clinician-rated) | 31 (Nortriptyline, 12; Pill-PBO, 19) | No | No | No |
Geller (1992) | DSM-III and RDC | Nortriptyline, 30 (10–140 mg/d); Pill-PBO, 30 | 8 | 6–12 (9.7) | 2.33 | NA | CGAS (clinician-rated) | 50 (Nortriptyline, 26; Pill-PBO, 24) | No | No | No |
Klein (1998) | DSM-III-R | Desipramine, 23 (50–300 mg/d); Pill-PBO, 22 | 6 | 13–18 (15.7) | 0.50 | USA | CGAS (clinician-rated) | 34 (Desipramine, 17; Pill-PBO, 17) | No | No | No |
Puig-Antich (1987) | K-SADS and RDC | Imipramine, 20 (3.25–5 mg/d per kg); Pill-PBO, 22 | 5 | 6–12 (9.1) | 1.53 | USA | CGAS (clinician-rated) | 38 (Imipramine, 16; Pill-PBO, 22) | No | No | No |
